TD-19 (erlotinib derivative) had a higher efficacy than erlotinib on growth inhibition and apoptosis in erlotinib-resistant non-small cell lung cancer H460 and H322 cell lines through the CIP2A-PP2A-AKT pathway. Here, CIP2A is linked to non-small cell lung carcinoma.